{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T23:17:50Z","timestamp":1769728670660,"version":"3.49.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,29]]},"DOI":"10.7759\/cureus.102541","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T11:49:01Z","timestamp":1769687341000},"source":"Crossref","is-referenced-by-count":0,"title":["Antibody Responses to SARS-CoV-2 in Cancer Patients in New York City During the 2020 Wave of the COVID-19 Pandemic"],"prefix":"10.7759","author":[{"given":"Maria","family":"Gianniki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuxuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Glembocki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marilia","family":"Bernardes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoginder","family":"Hinwar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaitlin","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Genovefa","family":"Papanicolaou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217871","article-title":"Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry","volume":"79","author":"Gianfrancesco M","year":"2020","unstructured":"Gianfrancesco M, Hyrich KL, Al-Adely S, et al.. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2020, 79:859-66. 10.1136\/annrheumdis-2020-217871","journal-title":"Ann Rheum Dis"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0979-0","article-title":"Determinants of severity in cancer patients with COVID-19 illness","volume":"26","author":"Robilotti EV","year":"2020","unstructured":"Robilotti EV, Babady NE, Mead PA, et al.. Determinants of severity in cancer patients with COVID-19 illness. Nat Med. 2020, 26:1218-23. 10.1038\/s41591-020-0979-0","journal-title":"Nat Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1172\/JCI141777","article-title":"Favorable outcomes of COVID-19 in recipients of hematopoietic cell transplantation","volume":"130","author":"Shah GL","year":"2020","unstructured":"Shah GL, DeWolf S, Lee YJ, et al.. Favorable outcomes of COVID-19 in recipients of hematopoietic cell transplantation. J Clin Invest. 2020, 130:6656-67. 10.1172\/JCI141777","journal-title":"J Clin Invest"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00934-x","article-title":"A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward","volume":"13","author":"Wang B","year":"2020","unstructured":"Wang B, Van Oekelen O, Mouhieddine TH, et al.. A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward. J Hematol Oncol. 2020, 13:94. 10.1186\/s13045-020-00934-x","journal-title":"J Hematol Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1200\/OP.21.00113","article-title":"SARS-CoV-2 seropositivity and seroconversion in patients undergoing active cancer-directed therapy","volume":"17","author":"Sun L","year":"2021","unstructured":"Sun L, Surya S, Goodman NG, et al.. SARS-CoV-2 seropositivity and seroconversion in patients undergoing active cancer-directed therapy. JCO Oncol Pract. 2021, 17:e1879-86. 10.1200\/OP.21.00113","journal-title":"JCO Oncol Pract"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2020-000889","article-title":"SARS-CoV-2 seroprevalence in oncology healthcare professionals and patients with cancer at a tertiary care centre during the COVID-19 pandemic","volume":"5","author":"Fuereder T","year":"2020","unstructured":"Fuereder T, Berghoff AS, Heller G, et al.. SARS-CoV-2 seroprevalence in oncology healthcare professionals and patients with cancer at a tertiary care centre during the COVID-19 pandemic. ESMO Open. 2020, 5:e000889. 10.1136\/esmoopen-2020-000889","journal-title":"ESMO Open"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.102102","article-title":"Seroprevalence of SARS-CoV-2-specific antibodies in cancer outpatients in Madrid (Spain): a single center, prospective, cohort study and a review of available data","volume":"90","author":"Cabez\u00f3n-Guti\u00e9rrez L","year":"2020","unstructured":"Cabez\u00f3n-Guti\u00e9rrez L, Custodio-Cabello S, Palka-Kotlowska M, Oliveros-Acebes E, Garc\u00eda-Navarro MJ, Khosravi-Shahi P. Seroprevalence of SARS-CoV-2-specific antibodies in cancer outpatients in Madrid (Spain): a single center, prospective, cohort study and a review of available data. Cancer Treat Rev. 2020, 90:102102. 10.1016\/j.ctrv.2020.102102","journal-title":"Cancer Treat Rev"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33148","article-title":"Low prevalence of IgG antibodies to SARS-CoV-2 in cancer patients with COVID-19","volume":"147","author":"Liu T","year":"2020","unstructured":"Liu T, Zeng G, Tao H, et al.. Low prevalence of IgG antibodies to SARS-CoV-2 in cancer patients with COVID-19. Int J Cancer. 2020, 147:3267-9. 10.1002\/ijc.33148","journal-title":"Int J Cancer"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.2471\/BLT.20.265892","article-title":"Infection fatality rate of COVID-19 inferred from seroprevalence data","volume":"99","author":"Ioannidis JPA","year":"2021","unstructured":"Ioannidis JPA. Infection fatality rate of COVID-19 inferred from seroprevalence data. Bull World Health Organ. 2021, 99:19-33F. 10.2471\/BLT.20.265892","journal-title":"Bull World Health Organ"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/imm.13349","article-title":"Development of a high-sensitivity ELISA detecting IgG, IgA and IgM antibodies to the SARS-CoV-2 spike glycoprotein in serum and saliva","volume":"164","author":"Faustini SE","year":"2021","unstructured":"Faustini SE, Jossi SE, Perez-Toledo M, et al.. Development of a high-sensitivity ELISA detecting IgG, IgA and IgM antibodies to the SARS-CoV-2 spike glycoprotein in serum and saliva. Immunology. 2021, 164:135-47. 10.1111\/imm.13349","journal-title":"Immunology"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0965-6","article-title":"Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections","volume":"26","author":"Long QX","year":"2020","unstructured":"Long QX, Tang XJ, Shi QL, et al.. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med. 2020, 26:1200-4. 10.1038\/s41591-020-0965-6","journal-title":"Nat Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2021.07.001","article-title":"Immune responses to COVID-19 vaccines in patients with cancer: promising results and a note of caution","volume":"39","author":"Griffiths EA","year":"2021","unstructured":"Griffiths EA, Segal BH. Immune responses to COVID-19 vaccines in patients with cancer: promising results and a note of caution. Cancer Cell. 2021, 39:1045-7. 10.1016\/j.ccell.2021.07.001","journal-title":"Cancer Cell"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/art.41914","article-title":"Humoral and cellular immune responses to SARS-CoV-2 infection and vaccination in autoimmune disease patients with B cell depletion","volume":"74","author":"Simon D","year":"2022","unstructured":"Simon D, Tascilar K, Schmidt K, et al.. Humoral and cellular immune responses to SARS-CoV-2 infection and vaccination in autoimmune disease patients with B cell depletion. Arthritis Rheumatol. 2022, 74:33-7. 10.1002\/art.41914","journal-title":"Arthritis Rheumatol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2021-324388","article-title":"Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab","volume":"70","author":"Kennedy NA","year":"2021","unstructured":"Kennedy NA, Goodhand JR, Bewshea C, et al.. Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab. Gut. 2021, 70:865-75. 10.1136\/gutjnl-2021-324388","journal-title":"Gut"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021012251","article-title":"COVID-19 in patients with hematologic malignancy","volume":"140","author":"Langerbeins P","year":"2022","unstructured":"Langerbeins P, Hallek M. COVID-19 in patients with hematologic malignancy. Blood. 2022, 140:236-52. 10.1182\/blood.2021012251","journal-title":"Blood"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00608-6","article-title":"Patterns of neutralizing humoral response to SARS-CoV-2 infection among hematologic malignancy patients reveal a robust immune response in anti-cancer therapy-naive patients","volume":"12","author":"Borgogna C","year":"2022","unstructured":"Borgogna C, Bruna R, Griffante G, et al.. Patterns of neutralizing humoral response to SARS-CoV-2 infection among hematologic malignancy patients reveal a robust immune response in anti-cancer therapy-naive patients. Blood Cancer J. 2022, 12:8. 10.1038\/s41408-022-00608-6","journal-title":"Blood Cancer J"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00152-0","article-title":"Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression","volume":"399","author":"Feikin DR","year":"2022","unstructured":"Feikin DR, Higdon MM, Abu-Raddad LJ, et al.. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. Lancet. 2022, 399:924-44. 10.1016\/S0140-6736(22)00152-0","journal-title":"Lancet"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(22)00146-3","article-title":"COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study","volume":"22","author":"Menni C","year":"2022","unstructured":"Menni C, May A, Polidori L, et al.. COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study. Lancet Infect Dis. 2022, 22:1002-10. 10.1016\/S1473-3099(22)00146-3","journal-title":"Lancet Infect Dis"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2021.11.006","article-title":"Efficacy of booster doses in augmenting waning immune responses to COVID-19 vaccine in patients with cancer","volume":"40","author":"Shapiro LC","year":"2022","unstructured":"Shapiro LC, Thakkar A, Campbell ST, et al.. Efficacy of booster doses in augmenting waning immune responses to COVID-19 vaccine in patients with cancer. Cancer Cell. 2022, 40:3-5. 10.1016\/j.ccell.2021.11.006","journal-title":"Cancer Cell"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/451627-antibody-responses-to-sars-cov-2-in-cancer-patients-in-new-york-city-during-the-2020-wave-of-the-covid-19-pandemic","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T11:49:02Z","timestamp":1769687342000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/451627-antibody-responses-to-sars-cov-2-in-cancer-patients-in-new-york-city-during-the-2020-wave-of-the-covid-19-pandemic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,29]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.102541","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,29]]}}}